Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Glioblastoma: KOL Insight [2018]

Product Code:
Publication Date:
February 2018

Are novel therapies set to revolutionise glioblastoma?

There has been little progress in the treatment of glioblastoma (GBM) for decades, and management of patients continues to remain challenging. ​N​ovel treatment approaches are ​advancing into late-stage development​, but what chances do these programmes have in reaching the market?

Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights on 3marketed and 19 pipeline therapies targeting various aspects of the GBM disease pathophysiology

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • Is Avastin’s (Roche) future in the GBM therapeutic strategy tenable? How do oncologists view bevacizumab and will the therapy continue to be a part of the treatment regimen for GBM?
  • Will Biocon’s BIOMAb EGFR reach the major US and EU markets? Phase II studies are ongoing for nimotuzumab in Cuba but how do KOLs rate its chances.
  • Could anti-PD-1/CTLA-4 agents become the new standard of care with TZM for GBM patients? How do KOLs view Opdivo/Yervoy’s chances of approval in GBM?
  • Could anti-PD-1/CTLA-4 agents become the new standard of care with TZM for GBM patients? How do KOLs view Opdivo/Yervoy’s chances of approval in GBM?
  • Will Merck/Pfizer’s avelumab + axitinib (Inlyta) combination find a place in recurrent GBM? What do KOLs think of GliAvAx study?
  • Can Medimmune (AZ)’s durvalumab/tremelimumab challenge BMS and Merck in the checkpoint inhibitor space? What potential do KOLs think anti-PD-1/CTLA-4 agents have in GBM?
  • How do oncologists view the DCVax-L vaccine product and what are the chances of Tocagen’s Toca 511 gene therapy reaching the market? Will these therapies have a role in GBM?
  • What questions do KOLs have regarding VBL Therapeutics’ ofranergene obadenovec (VB-111)? How do KOLs rate its chances?
  • According to KOLs, what challenges does AbbVie’s ABT-414 face? Will the EGFR inhibitor have broad application?
  • Can Astellas/Roche’s erlotinib + bevacizumab combination succeed in GBM? What do KOLs think of the the GLOBE study?
  • Will AbbVie’s PARP inhibitor have a future in GBM? What do KOLs think of AbbVie’s veliparib, AstraZeneca’s olaparib and BeiGene’s BGB-290?
  • What do KOLs think of CDK4/6 inhibitors? Will Lilly’s abemaciclib (Verzenio) reach the GBM market?
  • Will p-53 pathway be ‘druggable’ in GBM? Can ONC 201 succeed where many other have failed?
  • What challenges does DelMar’s VAL-083 face? Can the chemotherapy agent overcome the high hurdles and reach the market? What do KOLs say?
Request sample pages

Back to the top


“We don't have a drug that works in GBM, so any drug that works would be great.”
US Key Opinion Leader

“Clinical trials are overwhelmingly our first go-to option in the recurrent setting for glioblastoma patients. Again, we have a bunch of those that are ongoing at the moment.”
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Avastin (Roche/Genentech)
  • BIOMAb EGFR (Biocon)
  • Feron (Toray/Daiichi Sankyo)

Pipeline Therapies

  • Bavencio (avelumab; Merck Group)
  • DCVax-L (Northwest Biotherapeutics)
  • depatuxizumab mafodotin (ABT-414; AbbVie)
  • dianhydrogalactitol (VAL-083; DelMar)
  • veliparib (AbbVie)
  • flucytosine (Toca FC; Tocagen)
  • Imfinzi (durvalumab; MedImmune (AstraZeneca))
  • Inlyta (axitinib; Pfizer)
  • ITK 1 (BrightPath/FUJIFILM)
  • Keytruda (pembrolizumab; Merck & Co.)
  • ofranergene obadenovec (VB-111; VBL Therapeutics)
  • ONC 201 (Oncoceutics)
  • Opdivo (nivolumab; BMS/Ono Pharmaceutical)
  • ribociclib (Novartis)
  • Tarceva (erlotinib; Astellas/Genentech (Roche))
  • Tremelimumab (MedImmune (AstraZeneca))
  • Verzenio (abemaciclib; Eli Lilly)
  • vocimagene amiretrorepvec (Toca 511; Tocagen)
  • Yervoy (ipilimumab; BMS/Ono Pharmaceutical)

KOLs interviewed

KOLs from North America

  • Anonymous KOL, MD, Professor, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  • Glenn J Lesser, MD, Professor, Hematology & Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
  • Henry S Friedman, MD,  Professor of Neurosurgery; Deputy Director, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
  • John H Sampson, MD, PhD, MBA, MHSc, Professor & Chief, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USAB5
  • Timothy F Cloughesy, MD, Professor, Director, UCLA Neuro-Oncology Program, The Ronald Reagan UCLA Medical Center, University of California Los Angeles, CA, USA
  • Tom Mikkelsen, MD, FRCPC, President and Scientific Director, Ontario Brain Institute, Toronto, ON, Canada & Co-Director, Henry Ford Health System, Henry Ford Hospital, Detroit, MI, USA

KOLs from Europe

  • Andreas F Hottinger, MD, PhD, Department of Clinical Neurosciences, University Hospital Centre of Vaud, Division of Surgical Research & Gene Therapy Centre, Vaud, Switzerland
  • Anthony J Chalmers, MD, Professor/Chair of Clinical Oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK
  • Carmen Balana, MD, PhD, Head of Institut Catala d'Oncologia, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
  • Martin J van den Bent, MD, PhD, Professor, Head of the Neuro-Oncology Unit, Daniel den Hoed Cancer Centre, Erasmus University, Rotterdam, Netherlands
  • Michael Weller, MD, PhD, Professor, University Hospital Zurich, Department of Neurology, Zurich, Switzerland
  • Olivier L Chinot, MD, Professor & Head of Department, Assistance Publique Hôpitaux de Marseille, APHM, Hopital de la Timone, Marseille, France

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved